Ultragenyx Pharmaceutical
Stage
IPO | IPOTotal Raised
$135MDate of IPO
1/31/2014Market Cap
3.21BStock Price
45.92About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical is a developmental stage biotechnology company committed to bringing life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases, also known as orphan diseases, to market. The company focuses on metabolic and rare diseases that may affect small numbers of patients, but for which the medical need is high and there are no effective treatments. Ultragenyx intends to build a sustainable pipeline of safe and effective therapies to address these clinically underserved diseases.
Ultragenyx Pharmaceutical Headquarter Location
60 Leveroni Court
Novato, California, 94949,
United States
415-483-8800
Expert Collections containing Ultragenyx Pharmaceutical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Ultragenyx Pharmaceutical is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
260 items
Ultragenyx Pharmaceutical Patents
Ultragenyx Pharmaceutical has filed 40 patents.
The 3 most popular patent topics include:
- Molecular biology
- Rare diseases
- Biotechnology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
12/3/2018 | 5/17/2022 | Rare diseases, Prodrugs, Membrane biology, Syndromes, Autosomal recessive disorders | Grant |
Application Date | 12/3/2018 |
|---|---|
Grant Date | 5/17/2022 |
Title | |
Related Topics | Rare diseases, Prodrugs, Membrane biology, Syndromes, Autosomal recessive disorders |
Status | Grant |
Latest Ultragenyx Pharmaceutical News
May 18, 2022
US ultra-rare disease specialist Ultragenyx Pharmaceutical (Nasdaq: RARE) and gene and cell therapy company Abeona Therapeutics (Nasdaq: ABEO) have announced an exclusive license agreement for AAV gene therapy ABO-102 (now UX111) for the treatment of Sanfilippo syndrome type A (MPS IIIA). Under the terms of the agreement, Ultragenyx will assume responsibility for the ABO-102 program. Also, following regulatory approval, Abeona is eligible to receive… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login . If your trial has come to an end, you can subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK
Ultragenyx Pharmaceutical Web Traffic
Ultragenyx Pharmaceutical Rank
Where is Ultragenyx Pharmaceutical's headquarters?
Ultragenyx Pharmaceutical's headquarters is located at 60 Leveroni Court, Novato.
What is Ultragenyx Pharmaceutical's latest funding round?
Ultragenyx Pharmaceutical's latest funding round is IPO.
How much did Ultragenyx Pharmaceutical raise?
Ultragenyx Pharmaceutical raised a total of $135M.
Who are the investors of Ultragenyx Pharmaceutical?
Investors of Ultragenyx Pharmaceutical include HealthCap Venture Capital, TPG Biotech, F-Prime Capital, Pappas Ventures, Adage Capital Management and 7 more.
Who are Ultragenyx Pharmaceutical's competitors?
Competitors of Ultragenyx Pharmaceutical include Alexza Pharmaceuticals and 4 more.
You May Also Like
PhytoCeutica seeks to discover and develop botanical drugs for serious, untreated medical conditions. It does this through the utilization of a assay and informatics platform, as well as through controlled clinical trials.
CathWorks is developing an image-based functional flow reserve (FFR) measurement during coronary catheterization, replacing the pressure-wire based, drug-induced measurement currently performed. CathWorks's angiogram-based FFR (FFRangio) has met the need for a less invasive FFR assessment tool, to improve real-time functional assessment leading to treatment decisions, and to make coronary catheterization procedures safer, shorter, more accurate and comprehensive.
Can-Fite is an Israeli science-based biopharmaceutical company with the mission to develop treatments for autoimmune diseases and cancer. The company's drugs which piggyback on a natural mechanism, are small molecules, orally administered, induce specific activity towards their target pathological cells and demonstrated an excellent safety profile in human clinical studies.
Genz Bio is a biotechnology company developing novel IVD diagnostic solutions.
Symphony Allegor is a drug company focused on treatment of acute agitation in patients with schizophrenia and bipolar disorder
Hemorai develops a portable and affordable device, that is capable of providing accurate blood loss levels and alerting physicians of the actual hemoglobin and hematocrit levels, and applying correct treatment to prevent hemorrhagic shock and unnecessary blood transfusions.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.